Tubulis
- Health & Biotech
- Munich, DE
- Founded 2019
- Acquired
- tubulis.com
Develops next-generation antibody-drug conjugates for cancer, led by its TUB-040 candidate, and was acquired by Gilead in 2026.
$401MEquity raised in 2025–20262025 $401M · 2026 — · 1 equity round
$401MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 3 sources
Earlier rounds not yet sourced. Tubulis was founded in 2019 and raised before 15 Oct 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series CAmount$401MEUR 344MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 13
- Venrock1
- Andera Partners
- Ascenta Capital
- Bayern Kapital
- Blackstone
- Deep Track Capital
- EQT
- Fidelity
- Frazier Life Sciences
- High-Tech Gründerfonds
- Janus Henderson Investors
- Nextech Invest
- Wellington Management
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Parabilis MedicinesHealth · $975M in 2025–2026Shared: Nextech Invest, Frazier Life Sciences +2Quantum SystemsDefense · $1.6B in 2025–2026Shared: Wellington Management, Fidelity +1SkyryseDeep Tech · $300M in 2025–2026Shared: Venrock, FidelityAnthropicAI Labs · $113B in 2025–2026Shared: Fidelity, BlackstoneDatabricksEnterprise · $10B in 2025–2026Shared: Fidelity, BlackstoneThe Exploration CompanyDefense · $450M in 2025–2026Shared: EQT, Bayern Kapital
Also in the Munich hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Tubulis and its logo are trademarks of their owners, used here for identification only.
